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Background. Cardiac preconditioning is thought to be involved in the observed decreased
coronary artery reocclusion rate in patients with angina preceding myocardial infarction. We
prospectively examined whether preconditioning by sevoflurane would decrease late cardiac
events in patients undergoing coronary artery bypass graft (CABG) surgery.
Methods. Seventy-two patients scheduled for elective CABG surgery were randomized
to preconditioning by sevoflurane (10 min at 4 vol%) or placebo. For all patients, follow-up
of adverse cardiac events was obtained 6 and 12 months after surgery. Transcript levels for
platelet–endothelial cell adhesion molecule-1 (PECAM-1/CD31), catalase and heat shock protein
70 (Hsp70) were determined in atrial biopsies after sevoflurane preconditioning.
Results. Pharmacological preconditioning by sevoflurane reduced the incidence of late cardiac
events during the first year after CABG surgery (sevoflurane 3% vs 17% in the placebo group, log-
rank test, P=0.038). One patient in the sevoflurane group and three patients in the placebo group
experienced new episodes of congestive heart failure and three additional patients had coronary
artery reocclusion. Perioperative peak concentrations for myocardial injury markers were higher
in patients with subsequent late cardiac events [NTproBNP, 9031 (4125) vs 3049 (1906) ng
litre1, P<0.001; cTnT, 1.31 (0.88) vs 0.46 (0.29) mg litre1, P<0.001]. Transcript levels were
reduced for PECAM-1 and increased for catalase but unchanged for Hsp70 in atrial biopsies after
sevoflurane preconditioning.
Conclusions. This prospective randomized clinical study provides evidence of a protective role
for pharmacological preconditioning by sevoflurane in late cardiac events in CABG patients, which
may be related to favourable transcriptional changes in pro- and antiprotective proteins.
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Preconditioning can provide protection against myocardial
ischaemia and reperfusion damage and there is evidence to
demonstrate its occurrence in humans.1 2 Two phases of
protection have been described. Early preconditioning
occurs within minutes and is protective for 2–3 h, whereas
delayed preconditioning becomes effective within 12–24 h
and lasts for 3–4 days. Recently, nitroglycerin was demon-
strated to effectively induce delayed protection in patients
undergoing coronary angioplasty.3 While rapid phosphory-
lation and translocation of cellular key proteins are required
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in early preconditioning, transcriptional changes in pro- and
antiprotective proteins predominantly form the basic
mechanisms underlying the second window of protection.4
Previous experimental work and clinical observations sup-
port the concept that preconditioning may even exert longer-
term cardiovascular effects over and above the classic early
and delayed windows of protection. Brief ischaemic episodes
improved endothelial function in dogs5 and rats6 for up to
1 month. In the clinical setting, the presence of preinfarction
angina resulted in a lower in-hospital mortality rate in the
TAMI7 and TIMI-48 trials. However, to date, no clinical study
has prospectively addressed the effect of pharmacological
preconditioning on late cardiac events in high-risk patients.
We have demonstrated previously that pharmacological
preconditioning by sevoflurane increases postoperative
myocardial function as assessed by the biochemical marker
N-terminal pro-brain natriuretic peptide (NTproBNP) in
patients undergoing on-pump coronary artery bypass graft
(CABG) surgery.9 In this study, sevoflurane, which has been
shown previously to mimic preconditioning and to exert
significant cardiac protection against ischaemia and reperfu-
sion,4 was used for preconditioning.
The principal aims of the present study were to prospec-
tively evaluate the longer-term effects and potential mole-
cular mechanisms of pharmacological preconditioning with
sevoflurane on late cardiac events in a high-risk population.
Specifically, we proposed that preconditioning by sevo-
flurane would decrease late cardiac events in patients
undergoing CABG surgery.
Methods
Study population and preconditioning protocol
During 2001–02, 72 patients scheduled for elective CABG
surgery were enrolled in this study at three Swiss hospital
centres. The ethics committee at each centre approved the
study protocol, and all patients gave written informed con-
sent. We have previously reported on the immediate peri-
operative effects of preconditioning in these patients.9
Patients aged 40–80 yr scheduled for elective CABG surgery
on a cardiopulmonary bypass (CPB) circuit with cardiac
arrest were eligible for this study. Exclusion criteria
included concomitant aortic or valvular surgery, elevated
cardiac enzymes <24 h before surgery, unstable angina,
angina <24 h before surgery, haemodynamic instability
requiring inotropic support and administration of diazoxide,
nicorandil, sulfonylurea or theophylline.
Anaesthesia was induced in all patients with propofol or
etomidate, opioids and muscle relaxants and maintained
with a target-controlled infusion of propofol 2–5 mg ml1
to stabilize mean arterial pressure and heart rate within
20% of baseline values, with opioids, and muscle relax-
ants, as required. Patients were allocated randomly to pre-
conditioning with placebo or sevoflurane, using a sealed
envelope technique. Median sternotomy was performed to
cannulate the right atrium and the ascending aorta. Sevo-
flurane at 4 vol% or placebo (oxygen in air) was adminis-
tered during established CPB (2.4 litre min1 m2 body
surface area) for 10 min. The surgeons, anaesthetists and
perfusionists were blinded to the treatment by covering the
anaesthetic liquid level of the vaporizer, which was either
completely filled with sevoflurane or totally empty depend-
ing on the randomization. After preconditioning, the aorta
was cross-clamped and the cold (4C) cardioplegic solu-
tion was administered. No volatile anaesthetics were admi-
nistered during the study except for the pre-ischaemic
period in patients randomized to the sevoflurane group.
Core temperature was actively lowered or was allowed
to fall spontaneously. Atrial samples collected after pre-
conditioning but before aortic cross-clamping were used
for the determination of gene expression levels. The same
postoperative care was given to patients from both treat-
ment groups.
All study patients had prospectively scheduled medical
consultations, independent of the patients’ usual clinical
care, and 12-lead electrocardiogram (ECG), at the hospital
or with their general physicians 6 and 12 months after the
operation. Sixty-three per cent of the patients (45/72) had
their medical examinations in the hospital. For the remaining
patients, the general physicians were asked to prospectively
record information as detailed on the follow-up evaluation
form, which was sent to them. Each patient’s general
physician was instructed on collection of the required
data. Hospital charts, if applicable, were also reviewed.
The study end-points were late adverse cardiac events
including cardiac death, non-fatal myocardial infarction,
unstable angina, intercurrent coronary angioplasty or
CABG surgery, arrhythmias requiring rehospitalization,
and new episodes of congestive heart failure occurring
after the hospitalization for CABG surgery. Death was con-
sidered a result of cardiac cause if the patient died of myo-
cardial infarction, arrhythmia or congestive heart failure.
Myocardial infarction and unstable angina were defined
as previously reported.10 The following combination of cri-
teria was required for the diagnosis of congestive heart fail-
ure: (i) symptoms and signs of pulmonary congestion; (ii)
abnormal results on chest X-ray; (iii) a change in cardio-
vascular medication including at least the institution of
treatment with a diuretic agent. The primary outcome
variable combined all adverse cardiac events such as
myocardial infarction, unstable angina, congestive heart
failure, severe arrhythmias, coronary revascularization
and cardiac death.
Blood samples were obtained before surgery, in the inten-
sive care unit, and 24, 48 and 72 h after surgery for measure-
ment of cardiac troponin T (cTnT) (normal range <0.01 mg
litre1, sensitivity >0.01 mg litre1, intra- and interassay
coefficient of variation <5%) and NTproBNP (normal
range, males <227 ng litre1, females <334 ng litre1, sen-
sitivity >5 ng litre1 intra- and interassay coefficient of var-
iation <3%) (Roche Diagnostics, Mannheim, Germany).
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Transcript levels of platelet–endothelial cell adhesion
molecule-1 (PECAM-1), heat shock protein 70 (Hsp70)
and catalase from atrial samples collected after precondi-
tioning were determined after enrolment of all patients using
the following primers: PECAM-1 (GenBank accession
number NM000442), forward primer AGACGTGCAGT-
ACACGGAAG, reverse primer GATGTCCTTCCAGG-
GATGTG; Hsp70 (GenBank accession number L12723),
forward primer GGAGGTTCACAAGTCTGAGG, reverse
primer CCTTGGATCCAGCTTGAGAG; catalase (Gen-
Bank accession number AY028632), forward primer
CCACTGTTGCTGGAGAATCG, reverse primer CCGGA-
TCCTTCAGATGTGTC. For each gene-specific amplifica-
tion, 20 ml of cDNA was diluted in water before being used
as a template for the QuantiTect SybrGreen RT-PCR kit
(Qiagen, Hilden, Germany). RT-PCR quantification and
determination of expression levels were performed on an
ABI Prism 7700 Sequence Detector Real-Time PCR
machine (Perkin-Elmer, Foster City, CA, USA). Amplifica-
tion reactions were conducted with an initial step at 90C
for 3 min followed by 20–35 cycles. Intra- and interassay
coefficients of variation, as measured for the samples, were
<5%. All PCR reactions were performed in triplicate and
a-tubulin was used as a reference control.
The method of Kaplan and Meier was applied to evaluate
the occurrence of late cardiac events, and the Mantel–Cox
test was used to determine statistical significance. Two-
factor repeated-measures analysis of variance was used
to evaluate differences over time between groups. All
other data were analysed using unpaired t-tests or the
Mann–Whitney test. Categorical data were analysed using
the two-tailed Fisher exact test or the x2-test, as appropriate.
If not otherwise indicated, values represent mean (SD). SPSS
(SPSS, Chicago, IL USA) was used for statistical analyses.
Results
There were no major differences between the two groups
with respect to clinical data, except for phenylephrine
administration during the preconditioning process to main-
tain blood pressure above 50 mm Hg (Table 1). Also, as
previously reported,9 the use of opioids was similar between
the groups, and there was no difference in the need for
pharmacological inotropic support between groups at
the time of admission to the intensive care unit. Only one
placebo-treated patient required transient postoperative
inotropic support with an intra-aortic balloon pump.
There were no differences in cardiovascular medication
between groups before surgery (Table 2) or during fol-
low-up, with the exception of the use of diuretics, which
was increased in the placebo group 12 months after surgery.
Complete follow-up data was obtained in all patients. Late
adverse cardiac events (cardiac death, non-fatal myocardial
infarction, unstable angina, intercurrent coronary angioplasty,
coronary artery bypass grafting, arrhythmias requiring hospi-
talization and new episodes of congestive heart failure)
occurredinsevenpatientsandconsistedof threecoronaryartery
reocclusions and three new episodes of congestive heart failure
in the placebo group (6/35=17%), and one patient in the sevo-
flurane group (1/37=3%) experienced a new episode of con-
gestive heart failure (log rank test, P=0.038) (Fig. 1). None of
the patients died during the follow-up. One patient in the
sevoflurane group and two patients in the placebo group
had a perioperative non-transmural myocardial infarction.
Baseline values for NTproBNP and cTnT concentrations
were similar in patients with and without late cardiac events
(Fig. 2). However, peak perioperative serum concentrations
for NTproBNP and cTnT were significantly higher
(P<0.001) in patients with late cardiac events than in
those without such events (Fig. 2). The data suggest that
peak perioperative serum concentrations for NTproBNP
and cTnT after preconditioning may predict late cardiac
events.
Transcript levels for PECAM-1 were significantly
(P=0.019) lower in the sevoflurane group (Fig. 3). In con-
trast, the expression level for catalase was higher in the
sevoflurane group (P=0.001). Hsp70 expression was not
different between the two groups (P=0.59).
Discussion
To our knowledge, this study is the first prospective rando-
mized clinical trial evaluating the effect of cardiac precon-
ditioning on late cardiac events. The salient findings of the
study are as follows. First, pharmacological preconditioning
by the commonly available volatile anaesthetic sevoflurane
reduced late cardiac events in CABG patients and thereby
improved 1-yr event-free survival. Secondly, pharmacologi-
cal preconditioning activated a protective genetic pro-
gramme in human myocardium, which may be linked to
the observed late beneficial effects. Finally, perioperative
peak concentrations for NTproBNP and cTnT were markedly
increased in patients with subsequent late cardiac events.
Myocardial ischaemia and reperfusion induce a marked,
sustained endothelial dysfunction in the coronary endothe-
lium. In fact, long-term endothelial dysfunction was reported
to occur for up to 12 weeks after 60 min of ischaemia in a
Table 1 Patient characteristics. Data are mean (SD) [minimum–maximum],
number of patients or grafts, or median with percentiles (25th, 75th).
*P=0.0003 compared with placebo
Placebo (n=35) Sevoflurane (n=37)
Age (yr) 65 (10) [44–79] 62 (10) [44–80]
Sex (M/F) 28/7 31/6
Preoperative ejection
fraction (%)
57 (11) [40–76] 54 (12) [30–78]
Cross-clamp time (min) 60 (24) [15–121] 66 (22) [37–131]
Number of grafts 3.4 (0.9) [2–5] 3.5 (1.1) [2–6]
Median phenylephrine
use during preconditioning
(mg): median (percentiles)
0 (0–100) 200 (50–525)*
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dog model.11 An increasing body of evidence supports the
concept that preconditioning may have beneficial effects on
coronary vasculature including the microcirculation12 and,
in particular, the endothelium.13 Kaeffer and colleagues6
showed in an in vivo rat model that preconditioning effec-
tively prevents chronic reperfusion-induced coronary dys-
function. In their model, acetylcholine-dependent coronary
dilation was preserved in preconditioned coronaries as
opposed to non-preconditioned coronaries for up to 1
month after the ischaemic insult. More importantly, acute
as well as chronic electron microscopic changes in the
endothelium were absent after preconditioning. Collectively,
these results suggest that unfavourable long-term ischaemia/
reperfusion-induced functional and ultrastructural changes
can be effectively prevented by preconditioning.
In accordance with these observations, clinical studies
suggest that preinfarction angina, a clinical correlate of
preconditioning, not only increases the chance of rapid
reperfusion after thrombolytic therapy14 and reduces the
number of hypokinetic myocardial segments and infarct
size,15 but also affects the occurrence of delayed and late
cardiac events.7 8 Both the TAMI and TIMI-4 trials showed a
lower in-hospital mortality rate in patients with preinfarction
angina, which was not dependent on angiographically visi-
ble coronary collaterals. Moreover, increased 1-yr survival
was reported in the TIMI-4 study for patients with preinfarc-
tion angina. Anzai and colleagues16 demonstrated that
among patients with first Q-wave anterior infarction,
antecedent angina was associated with a lower incidence
of cardiac ruptures and less need for readmission for
Table 2 Medical therapy at the start of the study and during 1 yr of follow-up. Data are number (%) of patients. The use of cardiovascular medication was similar in
the two groups except for diuretics, which were used more often at 12 months in the placebo group (placebo vs sevoflurane: *P=0.062; {P=0.035). Fisher’s exact test
and the x2-test, respectively, were used to compare groups. ACEI=angiotensin-converting enzyme inhibitors; ATA=angiotensin receptor antagonists; NSAIDs=
non-steroidal anti-inflammatory drugs; COX-2-I=cyclooxygenase-2 inhibitors
Placebo (n=35) Sevoflurane (n=37)
Before hospital
admission
At hospital
discharge
At 6 months At 12 months Before hospital
admission
At hospital
discharge
At 6 months At 12 months
b-Blocker 28 (80%) 30 (85%) 30 (85%) 30 (85%) 34 (92%) 35 (94%) 35 (94%) 35 (94%)
Ca2+ blocker 6 (17%) 6 (17%) 6 (17%) 6 (17%) 6 (16%) 7 (19%) 6 (16%) 6 (16%)
Nitrates 14 (40%) 8 (22%) 10 (28%) 10 (28%) 20 (54%) 15 (40%) 12 (32%) 12 (32%)
ACEI/ATA 10 (28%) 15 (42%) 17 (48%) 16 (45%) 19 (51%) 19 (51%) 19 (51%) 19 (51%)
Statins 28 (80%) 29 (82%) 27 (77%) 27 (77%) 31 (83%) 31 (83%) 33 (89%) 35 (94%)
Aspirin 35 (100%) 35 (100%) 35 (100%) 35 (100%) 37 (100%) 37 (100%) 37 (100%) 37 (100%)
Diuretics 9 (25%) 8 (23%) 13 (37%)* 14 (40%){ 11 (29%) 7 (19%) 6 (16%) 6 (16%)
NSAIDs 7 (20%) 20 (57%) 15 (43%) 14 (40%) 8 (22%) 16 (43%) 14 (38%) 14 (38%)
COX-2-I 0 (0%) 0 (0%) 4 (11%) 4 (11%) 0 (0%) 0 (0%) 6 (16%) 6 (16%)
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Fig 1 Kaplan–Meier curves for adverse cardiac events during 1 yr of
follow-up after sevoflurane and placebo preconditioning in 72 patients
undergoing CABG surgery. Each plot represents the cumulative percentage
of patients remaining event-free. There is a significant difference in event-
free survival in patients with sevoflurane preconditioning compared with
patients with placebo (log rank test, P=0.038).
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Fig 2 Biomarkers of myocardial injury in patients with and without late
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heart failure during follow-up. Similarly, Ishihara and col-
leagues17 reported that prodromal angina, i.e. angina in the
24 h before infarction, but not previous angina, had a ben-
eficial effect on the long-term prognosis after infarction and
markedly improved 5-yr survival (83 vs 73%, P=0.009).
These observations are in line with the results of a recent
clinical study evaluating the biological significance of pre-
conditioning in humans.18 In this study, patients with cor-
onary artery disease and an effective preconditioning
mechanism, as measured by reduced ECG changes in
response to the second balloon inflation during coronary
angiography, showed a lower risk of death and non-fatal
myocardial infarction during a 1-yr follow-up. The reported
beneficial long-term effects may reflect a clinical counter-
part of late beneficial effects by preconditioning.
The mechanism by which preconditioning may prevent
late coronary events is not yet clear. However, it is tempting
to speculate that preconditioning may directly modify the
platelet–neutrophil–endothelial interaction by altering the
synthesis of various protective and antiprotective proteins.
Coronary endothelial dysfunction was previously reported
to be linked to future cardiovascular events.19 20 Using
microarray technology, volatile anaesthetics were recently
demonstrated to trigger a favourable genetic programme in
the myocardium compatible with endothelial protection.21
Decreased transcript levels for PECAM-1 and increased
levels of catalase transcript were observed in response to
anaesthetic preconditioning. PECAM-1 is an integral mem-
brane protein on the surface of platelets and leukocytes and
at the intercellular junctions of vascular endothelial cells
controlling the rate and direction of leukocyte migration
through the endothelium.22 Indeed, a significant role of
PECAM-1 in the transition of intracoronary atheromatous
plaques from the stable to the unstable state has been sug-
gested previously on the basis of the following observations.
First, platelet-bound PECAM-1 is increased in patients
with acute myocardial infarction,23 and administration of
anti-PECAM-1 antibodies reduced infarct size in animal
models.24 Secondly, increased platelet-bound PECAM-1
expression correlates with delayed and unsuccessful throm-
bolysis in patients with acute myocardial infarction.25 Anti-
inflammatory and anti-oxidant actions, including mitigation
of leukocyte transmigration by preconditioning, may well
prevent stable-to-vulnerable plaque transition and thereby
delay long-term coronary reocclusion. Similar mechanisms
have been suggested previously as part of the long-term
beneficial effects of short-term administration of atenolol
in cardiac risk patients undergoing surgery.10 These effects
may be particularly beneficial in the context of extracorpor-
eal circulation with direct contact of circulating blood with
the synthetic surfaces of the CPB, and inhibition of PECAM-
1 has been proposed as an attractive target for reducing
the inflammatory response to extracorporeal CPB.26 Inter-
estingly, in the current study catalase expression was
significantly up-regulated after sevoflurane preconditioning.
Scavenging of reactive oxygen species in ischaemia–
reperfusion may significantly attenuate endothelial injury.
Enhanced endothelial recovery after prolonged ischaemic
cardioplegic arrest was demonstrated to depend on catalase
activity.27 Also, PECAM-1-directed delivery of catalase to
the endothelium was shown to protect against vascular oxi-
dative stress.28 Hsp70, a chaperone which protects vital
protein structure and function during ischaemia, was not
differentially regulated. Collectively, these findings raise
the interesting possibility that activation of a favourable
genetic programme in the myocardium and particularly
the endothelium may be mechanistically linked to the
observed late beneficial effects.
There is an increasing number of studies,29 including
clinical ones, demonstrating a significant cardioprotective
effect of volatile anaesthetics in patients undergoing CABG
surgery.2 Laboratory investigations also stress the concept
that volatile anaesthetics may induce early and delayed
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Fig 3 Transcript levels in atrial samples after preconditioning of (A)
platelet–endothelial cell adhesion molecule-1 (PECAM-1), (B) catalase,
and (C) heat shock protein 70 (Hsp70) expressed as fold changes with
respect to a-tubulin. The transcript levels were determined for all patients
(n=72). PECAM-1: placebo vs sevoflurane, *P=0.019. Catalase: placebo vs
sevoflurane, {P=0.001. Hsp70, placebo vs sevoflurane, P=0.59. Data are
mean and SD.
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preconditioning in endothelial and smooth muscle cells,30
implying that systemic administration of these agents may
potentially protect a variety of other vital organs. Intriguingly,
preconditioning by sevoflurane was reported to attenuate
CPB-associated transient renal dysfunction in CABG
patients.9 Anti-inflammatory and anti-adhesive potentially
plaque-stabilizing actions were previously demonstrated for
sevoflurane and isoflurane in cardiac tissue,31 and thus may
delay the progression of coronary stenoses. The results of
this study now confirm and extend these findings to reducing
the incidence of late cardiac events in humans.
We have reported previously that sevoflurane precondi-
tioning significantly decreased perioperative NTproBNP
concentrations, but not cTnT concentrations.9 We now
show that late cardiac events were associated with signi-
ficantly higher perioperative peak concentrations for
NTproBNP and cTnT. Perioperative cTnT concentrations
were previously reported to predict postoperative compli-
cations after cardiac surgical procedures.32 Similarly, con-
centrations of brain natriuretic peptides, which directly
reflect myocardial contractile state, predicted long-term
cardiac function following CABG surgery.33 In a recent
study,34 excess cardiovascular risk including cardiovascu-
lar events, heart failure, atrial fibrillation, and stroke was
apparent at BNP concentrations well below the threshold
indicating heart failure. The results of this study demon-
strate an association of decreased perioperative peak
concentrations for cTnT and NTproBNP in sevoflurane-
preconditioned patients with a lower incidence of late
adverse cardiac events, but these observations need further
confirmation.
This study is the largest prospective randomized study
on preconditioning evaluating late cardiac events. Pre-
viously reported 1-yr cumulative cardiac complication
rates ranging from 1–20% after CABG surgery35 give this
study a power of 80% to detect a true difference of 20%
between groups. Nonetheless, our observations are based on
a small number of patients and thus require confirmation in
future large-scale clinical trials. Furthermore, a small num-
ber of candidate genes was assessed after preconditioning.
Future studies could use microarray technology at various
intraoperative time points to confirm and extend our
findings. Although no significant differences with respect
to pre- and postoperative cardiovascular drug therapies were
present between groups,36 we cannot completely rule out
a confounding effect of medication on cardiovascular
outcome. Also, the anaesthetic regimen was not strictly
standardized, with 15 patients in the placebo and 13 patients
in the sevoflurane group receiving etomidate for the induc-
tion of anaesthesia. However, there is no evidence at present
to suggest that the use of etomidate or propofol will affect
the preconditioning mechanisms.37 As more phenylephrine
was given during the preconditioning process in the sevo-
flurane group to maintain arterial pressure, we cannot
entirely exclude the possibility that the stimulation of
a-adrenergic receptors contributed to the observed effects.
However, in a separate multivariate analysis, the amount of
phenylephrine administered did not prove to be a significant
predictor of postoperative peak NTproBNP, making a
significant contribution of phenylephrine to the observed
protection unlikely.
Pharmacological preconditioning by sevoflurane impro-
ved 1-yr cardiac outcome in CABG patients. The present
study suggests that myocardial preconditioning by sevoflur-
ane may exert incremental long-term beneficial effects over
and above the established early and delayed windows of
protection, which may be linked to the activation of a
favourable genetic programme in the heart.
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